P38 Kinase Crystal Structure in complex with RO3201195

Experimental Data Snapshot

  • Resolution: 1.75 Å
  • R-Value Free: 0.239 
  • R-Value Work: 0.205 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.4 of the entry. See complete history


Discovery of S-[5-Amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]-methanone (RO3201195), and Orally Bioavailable and Highly Selective Inhibitor of p38 Map Kinase

Goldstein, D.M.Alfredson, T.A.Bertrand, J.Browner, M.F.Clifford, K.Dalrymple, S.Dunn, J.Freire-Moare, J.Harris, S.F.Labadie, S.S.La Fargue, J.Lapierre, J.M.Larrabee, S.Li, F.Papp, E.McWeeney, D.Ramesha, C.Roberts, R.Rotstein, D.San Pablo, B.Sjogren, E.So, O.Y.Talamas, F.X.Tao, W.Trejo, A.Villasenor, A.Welch, M.Welch, T.Weller, P.Whiteley, P.E.Young, K.Zipfel, S.

(2006) J Med Chem 49: 1562-1575

  • DOI: https://doi.org/10.1021/jm050736c
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    A novel class of highly selective inhibitors of p38 MAP kinase was discovered from high throughput screening. The synthesis and optimization of a series of 5-amino-N-phenyl-1H-pyrazol-4-yl-3-phenylmethanones is described. An X-ray crystal structure of this series bound in the ATP binding pocket of unphosphorylated p38alpha established the presence of a unique hydrogen bond between the exocyclic amine of the inhibitor and threonine 106 which likely contributes to the selectivity for p38. The crystallographic information was used to optimize the potency and physicochemical properties of the series. The incorporation of the 2,3-dihydroxypropoxy moiety on the pyrazole scaffold resulted in a compound with excellent drug-like properties including high oral bioavailability. These efforts identified 63 (RO3201195) as an orally bioavailable and highly selective inhibitor of p38 which was selected for advancement into Phase I clinical trials.

  • Organizational Affiliation

    Roche Palo Alto LLC, 3431 Hillview Avenue, R6-123, Palo Alto, California 94304, USA. David-M.Goldstein@roche.com

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Mitogen-Activated Protein Kinase 14372Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for Q16539 (Homo sapiens)
Explore Q16539 
Go to UniProtKB:  Q16539
PHAROS:  Q16539
GTEx:  ENSG00000112062 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ16539
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on PQB

Download Ideal Coordinates CCD File 
C19 H18 F N3 O4
Binding Affinity Annotations 
IDSourceBinding Affinity
PQB BindingDB:  2GFS IC50: min: 180, max: 700 (nM) from 5 assay(s)
PDBBind:  2GFS IC50: 700 (nM) from 1 assay(s)
Binding MOAD:  2GFS IC50: 700 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.75 Å
  • R-Value Free: 0.239 
  • R-Value Work: 0.205 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 45.292α = 90
b = 86.48β = 90
c = 124.055γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2006-04-18
    Type: Initial release
  • Version 1.1: 2008-05-01
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2017-10-18
    Changes: Advisory, Refinement description
  • Version 1.4: 2024-02-14
    Changes: Advisory, Data collection, Database references, Derived calculations